Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Inks R&D Deal With Indian Firm Potentially Worth $100 Million

This article was originally published in PharmAsia News

Executive Summary

Lilly's research and development agreement with India-based Nicholas Piramal India Limited gives the Indian firm the potential to earn $100 million in milestones and call-back payments, the firms said Jan. 12
Advertisement

Related Content

Deals Of The Week: UCB/Wilex, J&J/Vanderbilt, Alnylam/Cubist ...
Deals Of The Week: UCB/Wilex, J&J/Vanderbilt, Alnylam/Cubist ...
Eli Lilly In Asia Expansion Overdrive
Eli Lilly In Asia Expansion Overdrive
India's Nicholas Piramal Signs Second Potential $100 Million R&D Deal with Lilly
India's Nicholas Piramal Signs Second Potential $100 Million R&D Deal with Lilly
Rising Rupee Cuts Into Nicholas Piramal Revenues
Rising Rupee Cuts Into Nicholas Piramal Revenues
Indian Pharma Focusing On R&D, Licensing – Ranbaxy Exec
Advertisement
UsernamePublicRestriction

Register

SC065641

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel